Market Reports Center One Stop Market Research Shop
COPD Drugs Market Share, Size, Price, Growth, Trends and Forecast 2016 – 2020
Technavio Announces the Publication of its Research Report – COPD Drugs Market in China 2016-2020 Technavio recognizes the following companies as the key players in the COPD drugs market in China: AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis. Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab. Download Brochure now @ https://marketreportscenter.com/reports/313820/copd-drugs-market-inchina-2016-2020 Commenting on the report, an analyst from Technavio’ s team said: “A key trend which is boosting market growth is the increased focus on combination therapies. Combination therapies have a better advantage over monotherapies in providing better efficacy in the treatment of a condition. Manufacturers are now concentrating on developing combination therapies to treat COPD.These combination therapies reduce COPD-related hospitalizations and bring out better treatment outcomes in patients. Thus, the development of combinations therapies will increase the patient compliance toward the uptake of medications and help in the growth of the market.” According to the report, pollutants such as ground-level ozone, carbon dioxide, smog, fumes from vehicles, and particulates such as dust, soot, and pollen grains are known to trigger diseases such as COPD, asthma, bronchitis, and other respiratory issues. Airborne particles, sulfur dioxide, and nitrogen oxide are critical environment pollutants that worsen respiratory symptoms. Rapid globalization, urbanization, and industrialization have led to the rise in environmental pollution, which has increased the prevalence of COPD. Further, the report states that a major factor that could hamper market growth is the low diagnosis rate of COPD. It is difficult for physicians to recognize COPD at an early stage as the first symptoms of the